CONFIRM – Second phase III trial results for BG-12

 

REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – Just days after ECTRIMS, top-line  results from the second of two phase III trials of BG-12 were announced in a press release (www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1621631) and in a webcast to investors (www.biogenidec.com/investors.aspx?ID=5494).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page